![]() |
市場調查報告書
商品編碼
2032662
熱原檢測市場報告:按產品、檢測類型、應用和地區分類(2026-2034 年)Pyrogen Testing Market Report by Product (Instruments, Kits and Reagents, Services), Test Type (In-vitro Tests, LAL Tests, Rabbit Tests, and Others), Application (Pharmaceutical and Biologics, Medical Devices, and Others), and Region 2026-2034 |
||||||
2025年,全球熱原檢測市場規模達16億美元。展望未來,IMARC Group預測,到2034年,該市場規模將達到34億美元,2026年至2034年的複合年成長率(CAGR)為8.36%。推動該市場成長的因素包括:全球製藥和生技產業的擴張、心臟病、癌症和糖尿病等慢性疾病盛行率的上升,以及用於新療法上市和研發活動的資金增加。
監理合規和安全標準
熱原檢測市場的成長主要得益於美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 等衛生監管機構所推出的嚴格法規結構。美國醫療設備促進協會 (AAMI) 發布的 ST72;2002/R2010《細菌內毒素-調查方法、常規監測及批次檢測替代方案 (AAMI ST72)》文件說明了凝膠凝固法、光強度和動態檢測方法的基本原理,並建議對相關組件和成品進行熱原和內毒素檢測。這些法規要求對藥品、醫療設備和生物製藥進行嚴格的安全檢測,以確保其不含可能引起發燒並對患者構成嚴重風險的熱原。因此,製造商正在將熱原檢測納入其生產流程。
製藥和生物技術產業的進步
製藥和生物技術產業的成長,以及生物製藥產量的不斷增加,也改善了熱原檢測市場的前景。生物來源的生物製藥容易受到熱原污染。根據IMARC Group的數據顯示,2023年全球生物製藥市場規模達3,496億美元。展望未來,預計到2032年,熱原檢測市場規模將達到6,995億美元,2024年至2032年的複合年成長率(CAGR)為7.8%。隨著這些產業的擴張,對先進、可靠、快速的熱原檢測方法的需求也不斷成長。此外,這種需求正在推動檢測技術的創新,例如重組因子C(rFC)檢測,它是傳統鱟血檢測的合成替代方案。
醫療基礎建設
新興國家醫療基礎設施的發展以及對符合國際安全標準(包括無熱原認證)的醫療產品日益成長的需求,正在加速熱原檢測的需求成長。這種成長擴大了熱原檢測的地理市場,並鼓勵當地製造商採用先進的檢測技術進入全球市場。此外,醫療體系的發展和醫療支出的成長也推動了先進熱原檢測流程的採用和整合。同時,政府部門也在增加對醫療產業的投資,以促進公眾健康。例如,美國疾病管制與預防中心(CDC)已津貼32億美元,用於幫助美國各州、地方政府和地區加強公共衛生人員和基礎設施建設。這32億美元中包括根據《美國救援計畫法案》撥付的30億美元,各轄區將利用這筆資金招募、留住和培訓負責人,包括流行病學家、接觸者追蹤員、實驗室技術人員、社區衛生工作者和數據分析師——這些都是至關重要的公共衛生一線工作者。這項資金還包括1.4億美元,作為每個轄區加強和振興公共衛生基礎設施的新預算。
The global pyrogen testing market size reached USD 1.6 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 3.4 Billion by 2034, exhibiting a growth rate (CAGR) of 8.36% during 2026-2034. The market is propelled by the expanding pharmaceutical and biotechnology industries around the world, the increasing prevalence of chronic ailments such as heart diseases, cancer, and diabetes, and the launch of the new therapeutics and rising funding of research and development (R&D) activities.
Regulatory compliance and safety standards
The pyrogen testing market growth is significantly driven by the implementation of stringent regulatory frameworks by health authorities such as the FOOD and DRUGS ADMINISTRATION in the United States and the EUROPEAN MEDICINE AGENCY in Europe. The Association for the Advancement of Medical Instrumentation (AAMI) ST72:2002/R2010, Bacterial Endotoxins-Test Methodologies, Routine Monitoring, and Alternatives to Batch Testing (AAMI ST72) are documents that describe the fundamental principles of the gel clot, photometric, and kinetic test methods, and recommend that appropriate components and finished products be tested for the presence of pyrogens and endotoxins. These regulations require rigorous safety testing of pharmaceuticals, medical devices, and biological products to ensure they are free of pyrogens, which can induce fever and pose severe risks to patients. As a result, manufacturers are incorporating pyrogen testing in their production processes.
Advancements in pharmaceuticals and biotechnology industries
The growth of the pharmaceutical and biotechnology sectors and the increasing biologics production is also creating a favorable pyrogen testing market outlook. Biologics, derived from living organisms are susceptible to contamination by pyrogens. According to IMARC GROUP, the global biologics market size reached US$ 349.6 Billion in 2023. Looking forward, the pyrogen testing market value is expected to reach US$ 699.5 Billion by 2032, exhibiting a growth rate (CAGR) of 7.8% during 2024-2032. As these industries expand, the requirement for sophisticated, reliable, and rapid pyrogen testing methods is also increasing. Moreover, this demand is leading to innovations in testing technologies, such as recombinant factor C (rFC) assays, which offer a synthetic alternative to traditional horseshoe crab blood-derived tests.
Developing healthcare infrastructure
The developing healthcare infrastructure in emerging economies and the increasing need for medical products that meet international safety standards, including pyrogen-free certifications is escalating the pyrogen testing demand. This expansion broadens the geographic market for pyrogen testing and compels local manufacturers to adopt advanced testing technologies to participate in global markets. Moreover, the development of healthcare systems and the increased healthcare spending is increasing the adoption and integration of advanced pyrogen testing processes. Besides, government authorities are also investing in the healthcare industry to promote public health. For instance, CENTER for DISEASE CONTROL and PREVENTION has awarded $3.2 billion to help state, local, and territorial jurisdictions across the United States strengthen their public health workforce and infrastructure. The $3.2 billion includes $3 billion from the AMERICAN RESCUE PLAN ACT for jurisdictions to recruit, retain, and train their workforce, including critical frontline public health workers such as epidemiologists, contact tracers, laboratory scientists, community health workers, and data analysts. The funding also includes $140 million from a new appropriation for jurisdictions to strengthen and revitalize their public health infrastructure.
Kits and reagents accounts for the majority of the market share
Kits and reagents are user-friendly allowing for quick setup and execution of tests by laboratory personnel without the need for extensive specialized training. This convenience leads to faster turnaround times in testing. Besides, pre-packaged kits and reagents are more cost-effective than in-house testing methods. The costs associated with R&D, validation, and quality control of self-made tests can be prohibitively high, especially for smaller companies. Moreover, companies are acquiring and merging with other companies and launching new advanced products to expand their pyrogen testing market share. For instance, in March 2021, PromegaCorp. launched XpressAmp Direct amplification reagent.
LAL tests hold the largest share of the industry
LAL tests are highly sensitive to bacterial endotoxins, capable of detecting them at very low levels. The sensitivity of these tests is crucial for ensuring the safety of pharmaceuticals and medical devices. Moreover, due to its proven reliability, the LAL test has become the standard method for endotoxin testing and is widely trusted by regulatory authorities and manufacturers. Besides, the LAL test is recognized and recommended by major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Pharmacopoeia. For more than 30 years, FDA has accepted the use of a Limulus Amoebocyte Lysate (LAL) test for endotoxins in lieu of the rabbit pyrogens test.
Pharmaceutical and biologics represents the leading market segment
The biologics sector is growing rapidly, driven by advancements in biotechnology and an increasing focus on personalized medicine. This expansion contributes to a greater demand for pyrogen testing as more biologics enter research pipelines and commercial production. Moreover, pharmaceutical and biotechnology companies are investing heavily in research and development to create new drugs and biological products which necessitate rigorous safety testing, including pyrogen testing, to ensure that these innovations are safe for human use. For instance, California-based Amgen Inc. invests heavily in its research and development activities and its expenditure for research and development was US$ 4.8 Billion, US$ 4.2 Billion, and US$ 4.1 Billion, for 2021, 2020, and 2019, respectively, as per its 2021 company annual report. These factors are expanding the use of these testing in pharmaceutical and biologics thus creating a positive pyrogen testing market forecast.
North America leads the market, accounting for the largest pyrogen testing market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for pyrogen testing.
North America boasts an advanced healthcare infrastructure with a strong emphasis on regulatory compliance and patient safety. This infrastructure supports and demands high standards for medical products, influencing the need for pyrogen testing to ensure the safety of pharmaceuticals and medical devices. Besides, the healthcare expenditure in North America is among the highest in the world, with significant spending allocated to health innovation, including safety testing. According to the CENTERS FOR MEDICARE & MEDICAID SERVICES, the United States healthcare spending grew 4 pending grew 4.1% to reach $4.5 Trillion in 2022, faster than the increase of 3.2% in 2021. Besides, retail prescription drug spending increased 8.4% to $405.9 Billion in 2022, a faster rate than in 2021 when spending increased by 6.8%. This financial capability is escalating the need for pyrogen testing, across the healthcare and pharmaceutical sectors.